Jan Lichtenberg

Jan Lichtenberg is an accomplished executive with extensive experience in biotechnology and microtechnology sectors. Currently serving as Chief Executive Officer and Board Member at InSphero AG, Lichtenberg leads the company in the development of innovative organotypic microtissues for drug development in oncology and toxicology. Additional leadership roles include Chief Executive Officer at Syndya Therapeutics, focusing on 3D in-vitro NASH discovery, and a board position at Scailyte, which utilizes AI for understanding complex disease patterns. Previous positions include Head of R&D and Product Management at Hocoma AG, Head of Research and Development at Johnson Outdoors, and CEO and founder of AMMT GmbH, a leader in specialty wet etching equipment. Lichtenberg also has a robust academic background with a PhD in Microtechnology and Microfluidics from Université de Neuchâtel and additional research leadership roles at ETH Zurich and other institutions.